摘要
目的:探讨胃腺癌中YAP基因的状态及其与临床病理特征、预后的相关性。方法:用分子荧光原位杂交技术检测人胃腺癌组织中YAP基因改变情况,并探讨YAP基因与患者的临床病理特征及预后的相关性。结果:13.5%(13/96)的胃腺癌中存在YAP基因拷贝数的增加,YAP基因拷贝数的增加与胃腺癌的不良预后显著相关(P=0.04)。结论:部分胃腺癌中存在YAP基因拷贝数增加且与不良预后相关。分子荧光原位杂交对YAP基因的检测有望为胃癌组织的早期诊断、预防、临床治疗和预后判断提供新的靶点和可靠依据。
Objective: To investigate the correlation of YAP gene in gastric cancer and its clinical significance and prognosis. Methods: The YAP DNA expression in human gastric ductal adenocarcinoma tissues were detected by FISH and explored the relationship between clinical significance and prognosis of patients with YAP gene statue. Results:The positive rate of YAP gene in gastric carcinoma was 13. 5%( 13/96). The poor prognosis of gastric adenocarcinoma was significantly related to the increase of the copy number of YAP gene( P = 0. 04). Conclusion: The increase of the copy mumber of YAP gene in gastric adenocarcinoma was associated with a poor prognosis. Detection of YAP gene by FISH is expected to provide a new target and reliable basis for early diagnosis,prevention,clinical treatment and prognosis of gastric cancer.
引文
[1]Sudol M.Yes-associated protein(YAP65)is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product[J].Oncogene,1994,9(8):2145-2152.
[2]Lamar JM,Stern P,Liu H,et al.The Hippo pathway target,YAP,promotes metastasis through its TEAD-interaction domain[J].Proc Natl Acad Sci USA,2012,109(37):2441-2450.
[3]Juan WC,Hong W.Targeting the Hippo signaling pathway for tissue regeneration and cancer therapy[J].Genes,2016,7(9):1-25.
[4]Zhao B,Li L,Guan KL.Hippo signaling at a glance[J].J Cell Sci,2010,123(23):4001-4006.
[5]Mc Donald CB,Mc Intosh SK,Mikles DC,et al.Biophysical analysisof binding of WW domains of the YAP2 transcriptional regulator to PPXY motifs within WBP1 and WBP2 adaptors[J].Biochemistry,2011,50(44):9616-9627.
[6]Tang Y,Feinberg T,Keller ET.Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation[J].Nat Cell Biol,2016,18(9):917-929.
[7]Huang Z,Sun D,Hu JX,et al.Neogenin promotes BMP2 activation of YAP and Smad1 and enhances astrocytic differentiation in developing mouse neocortex[J].J Neurosci,2016,36(21):5833-5849.
[8]Haskins JW,Nguyen DX,Stern DF.Neuregulin 1-activated ERBB4interacts with YAP to induce Hippo pathway target genes and promote cell migration[J].Sci Signal,2014,7(355):1-7.
[9]Yi J,Lu L,Yanger K,et al.LATS1 and LATS2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ[J].Hepatology,2016,64(5):1757
[10]Xiao Q,Qian Z,Zhang W,et al.Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation[J].Oncotarget,2016,7(8):9513-9524.
[11]Zhao B,Wei X,Li W,et al.Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control[J].Genes&Development,2007,21:2747-2761.
[12]Pan D.The Hippo signaling pathwayin development and cancer[J].Developmental Cell,2010,19:491-505.
[13]Liu M,Zhao S,Lin Q,et al.YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues[J].Mol Cell Biol,2015,38(5):1449-1461.
[14]Zender L,Spector MS,Xue W,et al.Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach[J].Cell,2006,125:1253-1267.
[15]Overholtzer M,Zhang J,Smolen GA,et al.Transforming properties of YAP,a candidate oncogene on the chromosome 11q22 amplicon[J].Proc Natl Acad Sci,2006,103:12405-12410.
[16]Modena P,Lualdi E,Facchinetti F,et al.Identification of tumorspecific molecular signatures in intracranial ependymoma and association with clinical characteristics[J].J Clin Oncol,2006,24:5223-5233.
[17]Fernandez-LA,Northcott PA,Dalton J.YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation[J].Genes&Development,2009,23:2729-2741.
[18]Riina K,Ronald S,Ritva K,et al.19q13 Amplification is associated with high grade and stage in pancreatic cancer[J].Genes Chromosomes Cancer,2010,49(6):569-575.
[19]Steinhardt AA,Gayyed MF,Klein AP,et al.Expression of Yesassociated protein in common solid tumors[J].Human Pathology,2008,39:1582-1589.
[20]Zhang J,Lin Y,Lin Y,et al.Expression of YAP in human papillary thyroid cancer and its influence on cell growth[J].Chongqing Medicine,2016,45(12):1653-1655.[章杰,林义,林雅,等,YAP在人甲状腺乳头状癌中的表达及对细胞生长的影响[J].重庆医学,2016,45(12):1653-1655.]
[21]Liu CC,Liang JF,Zheng HX,et al.Expression and clinical significance of YAP in colorectal adenocarcinoma[J].Chinese Remedies&Clinics,2011,11(2):23-26.[刘丛丛,梁建芳,郑绘霞,等.YAP在结直肠腺癌组织中的表达及意义[J].中国药物与临床,2011,11(2):23-26.]
[22]Jia N,Zhang YL,Liu T,et al.Expression and location of YAP in osteosarcoma cells[J].Modern Oncology,2015,23(23):3330-3333.[贾楠,张迎龙,刘涛,等.YAP和TAZ在骨肉瘤组织中的表达及临床意义[J].现代肿瘤医学,2015,23(23):3330-3333.]
[23]Jiao S,Wang H,Shi Z,et al.A peptide mimicking VGLL4 functionacts as a YAP antagonist therapy against gastric cancer[J].Cancer Cell,2014,25(2):166-180.
[24]Wang YP,Tang DX.Expression of Yes-associated protein in livercancer and its correlation with clinicopathological features and prognosis of liver cancer patients[J].International J Clinical and Experimental Medicine,2015,8(1):1080-1086.
[25]He DL,Liu Y,Xia LP,et al.Expressions and significance of Yes-associated protein and p73 in breast carcinoma[J].Cancer Research on Prevention and Treatment,2011,38(12):1401-1404.[何冬雷,刘玉,夏立平,等.YAP、p73在乳腺癌组织中的表达及意义[J].肿瘤防治研究,2011,38(12):1401-1404.]
[26]Zhang L,Yang S,Chen X,et al.The Hippo pathway effector,YAP,pegulates motility,invasion and castration-resistant growth of prostate cancer cells[J].Mol Cell Biol,2015,2:102-115.
[27]Cao WJ,Xu YJ,Xu ZJ,et al.Expression of Yes-associated protein in colorectal carcinoma and its effect on tumor cell proliferation[J].J Chin Physician,2013,15(7):885-889.[曹伟军,徐亦君,徐兆军,等.YAP在结直肠癌中的表达及对结直肠癌增殖的影响[J].中国医师杂志,2013,15(7):885-889.]
[28]Muramatsu T,Imoto I,Matsui T,et al.YAP is a candidate oncogene for esophageal squamous cell carcinoma[J].Carcinogenesis,2011,32(3):389-398.
[29]Lorenzetto E,Brenca M,Boeri M,et al.YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes[J].Oncotarget,2014,5(9):2608-2621.
[30]Baldwin C,Garnis C,Zhang L,et al.Multiple microalterations detected at high frequency in oral cancer[J].Cancer Research,2005,65:7561-7567.
[31]Snijders AM,Schmidt BL,Fridlyand J,et al.Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma[J].Oncogene,2005,24:4232-4242.
